Biomedical subjects

Claudio Borghi

Publications and source records attributed to Claudio Borghi.

25 records · Page 2Linked to original sources

PubMed2003

[Hypercholesterolemia as cardiovascular risk in hypertensive patients. Therapeutic implications: efficiency of statins].

Several epidemiological studies have already shown that hypertensive subjects are very often characterized by elevated levels of serum cholesterol, which increase the risk of cardiovascular diseases. It has been suggested that only the contemporary treatment of both cardiovascular risk factors is able to improve the individual cardiovascular risk profile even if, up to date, we still have limited results from large clinical trials regarding the impact of multiple therapeutic intervention in the prevention of cardiovascular diseases. More scientific evidences came from the results of several clinical studies that have investigate the preventive and therapeutic role of hypolipidemic drugs, especially statins, in subjects with hypercholesterolemia and high blood pressure, particularly when those diseases are associated with diabetes. Indeed, this class of hypolipidemic agent has already shown to improve the individual lipid profile and contemporary to reduce the blood pressure values in the hypertensive hypercholesterolemic subjects acting synergistically with some class of anti-hypertensive drugs.

Anticholesteremic Agents↗

PubMed2002

Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials.

ACE-inhibitors (ACE-I) represent effective drugs more and more widely used in acute myocardial infarction (AMI) patients, in post AMI patients and mainly, today, in CHF patients.A complete review of the scientific literature and of all the randomized controlled clinical trials (RCTs), where ACE-I have been tested directly or in association with other drugs, have been performed. ACE-I effects on total mortality (TM) and arrhythmic mortality (AM) and other composite clinical endpoints have been evaluated. It is well known that frequent ventricular arrhythmias (VA) and a high incidence of sudden death (SD) can be documented in CHF patients; nevertheless a direct relationship between VA, TM, and AM has not been clearly demonstrated; neither beneficial effects, on the same endpoints, of the treatment and suppression of ambient VA in CHF. Conversely, sometimes clear negative effects on both TM and AM have been observed. According to individual studies and two recent complete and large metanalysis, ACE-I were unable to reduce AM, but they reduced TM. Furthermore, they can affect and modify many, if not all, of the triggering factors of VA and SD in this context. Differently from ACE-I, betablockers (BB) have been clearly associated with a reduction in TM and AM, in the same context. Thus, at present time, ACE-I, with or without BB, should be considered the standard therapy in all patients with CHF, if not contraindicated. Angiotensin II antagonists (AII-a) probably represent a comparably effective treatment, in all CHF patients and mainly in those patients, suffering from side effects or showing intolerance to ACE-I, but we are still lacking definitive data from RCTs. In many RCTs, conducted with traditional antiarrhythmic drug therapy (ADT), these drugs have been widely used, contributing probably, in a consistent way, to some of the positive results of these studies. All primary and some secondary implantable defibrillators (ICD) RCTs, in the prevention of SD, have included these drugs as the standard treatment of the underlying cardiac disease, with or without CHF. The same therapeutical strategy is regularly applied in all biventricular pacing (BP) RCTs, with or without the ICD. These trials are supposed to assess the reduction in TM and AM, preventing deterioration or progression of CHF and improving the quality of the patients' s life.Finally, according to these clinical evidences, in the last part of the review, we stress the need for a more widespread implementation of ACE-I and AII-a in treating CHF patients.

Adrenergic beta-Antagonists↗

PubMed2002

Relative role of systolic, diastolic and pulse pressure as risk factors for cardiovascular events in the Brisighella Heart Study.

OBJECTIVE: The objective of this study was to determine the contribution of elevated blood pressure parameters to the long-term incidence of cardiovascular events. DESIGN: A prospective, population-based longitudinal epidemiological cohort. SETTINGS: The population of the town of Brisighella. PATIENTS: The Brisighella Heart Study involved 2939 randomly selected residents of Brisighella, Italy aged 14 to 84 years, free of cardiovascular (CV) disease at enrollment and followed since 1972. Subjects were clinically evaluated at baseline and every 4 years following enrollment when extensive clinical and laboratory data were obtained in addition to the assessment of morbidity and mortality. MAIN OUTCOME MEASUREMENTS: The Cox regression analysis, adjusted for the main risk factors for CV disease was used to determine the independent prognostic significance of systolic, (SBP), diastolic (DBP), and pulse pressure (PP). The events of interest were coronary heart disease (CHD) and cerebrovascular disease (CVD). RESULTS: Adjusted hazard ratios (HRs) for combined CHD + CVD at SBP categories of 120-139, 140-159, and 159 mmHg were 1.45 [95% confidence interval, (CI), P= 0.035], 1.88 (95% CI, P= 0.0008), and 2.31 (95% CI, P<0.0001), respectively. For DBP ranges of 70-79, 80-89, and 89 mmHg, HRs were 0.91 (95% CI, P= 0.677), 1.33 (95% CI, P= 0.169), and 1.65 (95% CI, P= 0.029), respectively. PP ranges from 54-67 and 67 mmHg were associated with HRs of 1.23 (95% CI, P= 0.149), and 1.38 (95% CI, P= 0.030), respectively. Similar results were seen for CVD and CHD as separate endpoints. CONCLUSIONS: The present study demonstrates that SBP is a stronger predictor of cardiovascular events than DBP in the Brisighella population. The added prognostic significance of PP is also demonstrated, particularly if PP exceeds 67 mmHg.

Adolescent↗

PubMed2002

Interactions between hypercholesterolemia and hypertension: implications for therapy.

PURPOSE OF THE REVIEW: The purpose of the present review is to summarize the available information that supports the therapeutic role for the concomitant and aggressive management of hypercholesterolemia and hypertension. RECENT FINDINGS: A concomitant management of hypertension and high-plasma cholesterol has been suggested to significantly reduce the extent of cardiovascular complications. Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been demonstrated to be very effective in the treatment of patients with hypercholesterolemia where they reduce the rate of coronary and cerebrovascular complications. This benefit is largely extended to the hypertensive population. Very recently some studies have demonstrated the capacity of statins to improve blood pressure control in patients with hypertension and this effect, which has not been demonstrated for the other lipid-lowering drugs, could be very important in the clinical management of overall cardiovascular risk. SUMMARY: These findings confirm that the prevention of cardiovascular diseases should be based on the aggressive treatment of many different risk factors. This is particularly true for patients with hypertension and hypercholesterolemia for whom the negative interaction between risk factors could be effectively managed by an appropriate choice of both antihypertensive and lipid-lowering drugs.

Antihypertensive Agents↗

PubMed2002

The treatment of hypertension in pregnancy.

The hypertensive disease that occurs during pregnancy is a multifaceted clinical condition whose accurate diagnosis, not limited to the evaluation of degree of the hypertensive derangement, is crucial for a correct therapeutic approach. In particular, chronic hypertension pre-existing before pregnancy should be clearly differentiated from the hypertensive disease induced by pregnancy and particularly from pre-eclampsia. Non-pharmacological measures of intervention have not been proven to improve both maternal and fetal outcome. Severe hypertension during pregnancy (blood pressure > 170/110 mmHg) should be immediately treated with drugs that have been proven to prolong pregnancy and to improve both maternal and fetal outcome. In patients with mild to moderate hypertension, both chronic and pregnancy induced, antihypertensive treatment improves the maternal outcome, whereas no clear-cut evidence of benefit have been reported at the fetal level. Among the different antihypertensive drugs that have been reported to be effective, safe and well tolerated during pregnancy, methyldopa, beta-blockers and particularly calcium channel blockers (nifedipine) represent the more suitable solution.

Antihypertensive Agents↗

PubMedDate not supplied

Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension.

A large proportion of patients have both hypertension and hypercholesterolemia, two of the most important risk factors for cardiovascular diseases. Statins are the most widely used drugs for the treatment of plasma lipid abnormalities and have been reported to interact with elevated blood pressure. A reduction in blood pressure associated with the use of these agents has been reported in patients with untreated hypertension and in patients treated with antihypertensive drugs, particularly angiotensin-converting enzyme inhibitors and calcium channel blockers. This effect on blood pressure control has also been observed in diabetic patients. The mechanism responsible for the hypotensive effect seems to be largely independent of the effect of statins on plasma cholesterol, and probably is related to the interaction of the medications with endothelial function or angiotensin II receptors. The capacity of statins to improve blood pressure control may represent a useful tool for improvement in the prevention of cardiovascular diseases.

Angiotensin II↗

PubMedDate not supplied

The relationship between systolic blood pressure and cardiovascular risk--results of the Brisighella Heart Study.

We examined the relationship of systolic (SBP) and diastolic (DBP) blood pressure, and pulse pressure to coronary heart disease and cerebrovascular disease risk in a prospective population-based European cohort. The Brisighella Heart Study included 2939 men and women between the ages of 14-84 without prior coronary heart disease or cerebrovascular disease and not taking antihypertensive therapy at baseline. Cox regression was used to obtain hazard ratios (HRs) for coronary heart disease and cerebrovascular disease as a function of baseline blood pressure parameters over a 23-year follow-up. Higher combined coronary heart disease and cerebrovascular disease risk was evident in comparison to the referent of <120 mm Hg, with a 44% increased risk at SBP 120-139 mm Hg (HR, 1.44; 95% confidence interval [CI], 1.00-2.09; p=0.052), 76% increased risk at SBP 140-159 mm Hg (HR, 1.76; 95% CI, 1.16-2.69; p=0.009), and 109% increased risk at SBP >or=160 mm Hg (HR, 2.09; 95% CI, 1.31-3.35; p=0.0021). Trends of increasing risk with increasing levels of blood pressure were significant for SBP and pulse pressure, (p<0.0001) but not for DBP (p=0.058). In this European cohort, SBP was a stronger predictor of coronary heart disease and cerebrovascular disease events than DBP, and an increase in risk was already evident with high-normal SBP (120-139 mm Hg). The prognostic significance of pulse pressure was also demonstrated. The importance of SBP as seen in the Framingham Heart Study may be generalized to a European population with differences in diet and other risk factors.

Adolescent↗